Patents by Inventor MANISH KUMAR UMRETHIA

MANISH KUMAR UMRETHIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11931455
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: March 19, 2024
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Publication number: 20230372238
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: July 31, 2023
    Publication date: November 23, 2023
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Patent number: 11738020
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: August 29, 2023
    Assignees: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LIMITED
    Inventors: Sandip Mehta, Manish Kumar Umrethia, Jayanta Mandal
  • Publication number: 20230263796
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Application
    Filed: May 2, 2023
    Publication date: August 24, 2023
    Inventors: Sandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
  • Publication number: 20230255885
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an anti-cancer active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the anti-cancer active pharmaceutical ingredient is selected from ibrutinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, and capecitabine.
    Type: Application
    Filed: August 16, 2019
    Publication date: August 17, 2023
    Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTD
    Inventors: SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
  • Publication number: 20230158018
    Abstract: Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include temozolomide, lenalidomide, Oxaliplatin, Cisplatin, Carboplatin, 5-fluorouracil, irinotecan, topotecan, cyclophosphamide, doxorubicin, vincristine, vinblastine, Melphalan, Chlorambucil, Dacarbazine, Daunorubicin, Epirubicin, Mitoxantrone, Etoposide, Teniposide, Azacitidine, Cytarabine, Gemcitabine, vinoralbine, Pemetrexed, a derivative thereof, or a combination thereof. The pharmaceutical compositions may be administered as an oral suspension. Other embodiments are directed towards methods of using and methods of making such formulations.
    Type: Application
    Filed: September 13, 2019
    Publication date: May 25, 2023
    Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTD
    Inventors: VIJAY PATEL, SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
  • Publication number: 20220023288
    Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
    Type: Application
    Filed: August 16, 2019
    Publication date: January 27, 2022
    Inventors: SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL
  • Publication number: 20210308044
    Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.
    Type: Application
    Filed: August 16, 2019
    Publication date: October 7, 2021
    Applicants: FTF PHARMA PRIVATE LIMITED, LM MANUFACTURING LTD
    Inventors: SANDIP MEHTA, MANISH KUMAR UMRETHIA, JAYANTA MANDAL